VIDEO: Phentolamine drops rapidly reverse mydriasis
In this Healio Video Perspective, Cathleen M. McCabe, MD, discusses a presentation from the ESCRS meeting on phentolamine 0.75%.
The FDA recently approved Ryzumvi (phentolamine ophthalmic solution 0.75%, Ocuphire Pharma/Viatris), formerly known as Nyxol, for the treatment of pharmacologically induced mydriasis.
“What is unique about this compound is that it is an alpha-1 blocker, so it blocks the action of the pupil dilator muscle, and it does so without affecting the ciliary body and without affecting the sphincter of the pupil,” she said.
Phentolamine has three indications: mitigation of nighttime visual disturbances, presbyopia correction and reversal of mydriasis. In the MIRA-2 and MIRA-3 studies, it was tested with three different mydriatics, showing the ability to rapidly reverse mydriasis.
Collapse
Healio Interviews
Read more about